- Home
- PNNT vs EBS Comparison
PNNT vs EBS Comparison
Compare PNNT & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNNT
- EBS
- Stock Information
- Founded
- PNNT 2007
- EBS 1998
- Country
- PNNT United States
- EBS United States
- Employees
- PNNT N/A
- EBS N/A
- Industry
- PNNT Finance: Consumer Services
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- PNNT Finance
- EBS Health Care
- Exchange
- PNNT Nasdaq
- EBS Nasdaq
- Market Cap
- PNNT 423.8M
- EBS 423.6M
- IPO Year
- PNNT 2007
- EBS 2006
- Fundamental
- Price
- PNNT $6.53
- EBS $12.48
- Analyst Decision
- PNNT Sell
- EBS Strong Buy
- Analyst Count
- PNNT 5
- EBS 2
- Target Price
- PNNT $6.38
- EBS $13.50
- AVG Volume (30 Days)
- PNNT 463.2K
- EBS 1.3M
- Earning Date
- PNNT 11-24-2025
- EBS 10-29-2025
- Dividend Yield
- PNNT 14.70%
- EBS N/A
- EPS Growth
- PNNT 21.65
- EBS N/A
- EPS
- PNNT 0.80
- EBS 1.35
- Revenue
- PNNT $130,923,000.00
- EBS $788,900,000.00
- Revenue This Year
- PNNT N/A
- EBS N/A
- Revenue Next Year
- PNNT N/A
- EBS $19.24
- P/E Ratio
- PNNT $8.19
- EBS $9.24
- Revenue Growth
- PNNT N/A
- EBS N/A
- 52 Week Low
- PNNT $5.72
- EBS $4.02
- 52 Week High
- PNNT $7.53
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- PNNT 46.36
- EBS 73.54
- Support Level
- PNNT $6.43
- EBS $9.21
- Resistance Level
- PNNT $6.53
- EBS $13.41
- Average True Range (ATR)
- PNNT 0.12
- EBS 0.66
- MACD
- PNNT 0.02
- EBS 0.26
- Stochastic Oscillator
- PNNT 57.56
- EBS 79.06
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.